Acetyl-11-keto-beta-boswellic acid

Context

Boswellia serrata resin contains several boswellic acids: beta-boswellic acid, acetyl-beta-boswellic acid, 11-keto-beta-boswellic acid, and acetyl-11-keto-beta-boswellic acid (AKBA). Of these, AKBA is by a wide margin the most potent 5-LOX modulator in vitro and in vivo. Standardized extracts target 65% AKBA because that concentration delivers the active compound at levels associated with clinical effect in human trials.

Whole-resin boswellia extracts typically contain 1-7% AKBA by weight, far below the therapeutic range. This is why standardization matters in supplement labeling: a generic boswellia label without AKBA disclosure is a black box.

Why it matters for joint health

AKBA is the molecular reason boswellia has a different clinical profile than NSAIDs. By modulating 5-LOX selectively, AKBA reduces leukotriene-driven inflammation without touching the COX pathway, which means no gastric mucosa compromise and no cardiovascular signature associated with long-term NSAID use. The trade-off is slower onset (7-14 days) because modulating a chronic inflammatory signaling enzyme takes days, not hours.